Department of Pharmaceutics, Khalsa College of Pharmacy, Amritsar 143001, Punjab,India.
Recent Adv Antiinfect Drug Discov. 2021;16(3):182-195. doi: 10.2174/2772434416666211111105854.
Luliconazole is a broad-spectrum antifungal agent with impactful fungicidal and fungistatic activity. It has shown exceptional potency against miscellaneous fungal strains like Candida, Aspergillus, Malassezia, Fusarium species and various dermatophytes. Luliconazole belongs to class II of the Biopharmaceutical Classification System with low aqueous solubility. Although it is available conventionally as 1% w/v topical cream, it has limitations of lower skin permeation and shorter skin retention. Therefore, nanoformulations based on various polymers and nanostructure carriers can be employed to overcome the impediments regarding topical delivery and efficacy of luliconazole. In this review, we have tried to provide insight into the literature gathered from authentic web resources and research articles regarding recent research conducted on the subject of formulation development, patents, and future research requisites of luliconazole. Nanoformulations can play a fundamental role in improving topical delivery by escalating dermal localization and skin penetration. Fabricating luliconazole into nanoformulations can overcome the drawbacks and can efficiently enhance its antimycotic activity. It has been concluded that luliconazole has exceptional potential in the treatment of various fungal infections, and therefore, it should be exploited to its maximum for its innovative application in the field of mycology.
卢立康唑是一种广谱抗真菌药物，具有显著的杀菌和抑菌活性。它对各种真菌菌株（如念珠菌、曲霉、糠秕马拉色菌、镰刀菌属和各种皮肤真菌）具有非凡的效力。卢立康唑属于生物制药分类系统 II 类，水溶性低。虽然它通常以 1% w/v 的局部乳膏形式存在，但它存在皮肤渗透能力较低和皮肤滞留时间较短的局限性。因此，可以使用基于各种聚合物和纳米结构载体的纳米制剂来克服卢立康唑局部递药和疗效方面的障碍。在这篇综述中，我们试图从真实的网络资源和研究文章中收集有关卢立康唑制剂开发、专利和未来研究需求的文献，提供深入的见解。纳米制剂可以通过增加皮肤定位和穿透来改善局部递药，发挥基础性作用。将卢立康唑制成纳米制剂可以克服这些缺点，并有效地提高其抗真菌活性。结论是，卢立康唑在治疗各种真菌感染方面具有特殊的潜力，因此应充分利用其在真菌学领域的创新应用。
